Lanabecestat - AstraZeneca

Drug Profile

Lanabecestat - AstraZeneca

Alternative Names: AZD3293; BACE inhibitor - AstraZeneca; Beta secretase inhibitor - AstraZeneca; LY 3314814

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Pharmaceuticals; AstraZeneca
  • Developer AstraZeneca; Eli Lilly
  • Class Antidementias; Imidazoles; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 17 Apr 2018 Eli Lilly in collaboration with AstraZeneca plans a phase I trial for Hepatic impairment in healthy volunteers in USA , (NCT03499041)
  • 16 Feb 2018 Eli Lilly and AstraZeneca completes a phase I trial in healthy volunteers in United Kingdom (PO) (NCT03222427)
  • 15 Jan 2018 Phase-I clinical trials in Alzheimer's disease (In volunteers) in United Kingdom (IV) (NCT03222427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top